Informations

Introduction: Challenging Traditional Cognition, The Systematic Layout of the EHA Guidelines Committee At the beginning of the meeting, Professor Steffen Koschmieder from Aachen, Germany, a member of the EHA Guidelines…

Guideline Update Background: Addressing the Unprecedented Complexity of Treatment Choices At the beginning of the meeting, Professor Peter Sonneveld, President of EHA-EMN, delivered the opening remarks. He pointed out that…

Development and Core Framework of the New Guidelines: A Decade of Refinement At the beginning of the meeting, Professor Massimo Federico reviewed the developmental history of PTCL guidelines. He noted…

The human hematopoietic system is responsible for vital functions of substance transport and immune defense, with an astonishing cell turnover rate—approximately 90% of all cells are replaced daily by the…

As a star in the current immunotherapy landscape, Chimeric Antigen Receptor T-Cell (CAR-T) therapy has achieved tremendous success in some hematological tumors. However, its limitations are becoming increasingly apparent. “Currently…

Acute Myeloid Leukemia (AML), as a highly heterogeneous malignancy, presents immense challenges to precise clinical subtyping and treatment due to its complex biological characteristics. Although existing clinical guidelines, such as…

The 2025 European Hematology Association (EHA) Annual Meeting was grandly held both online and in-person, gathering top experts and scholars from the global hematology community. During the highly anticipated Presidential Symposium, Professor Nicola Cooper, an immune-hematologist from Imperial College London, delivered a keynote speech on “Immune Thrombocytopenia (ITP): From Biology to Targeted Therapy.” She systematically…

Precision Diagnosis and Risk Stratification: The Cornerstone of Individualized Treatment The new EHA guidelines first emphasize the central role of precise diagnosis and comprehensive risk assessment in the management of…